4 4D MOLECULAR THERAPEUTICS IN
| Market Cap | $499.93M |
| P/E Ratio | — |
| Forward P/E | -2.52 |
| Dividend Yield | — |
| Beta | 3.01 |
| 52W Range | $2.24 - $12.34 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 13 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Gupta AshooVP, Finance and Controller | Sale | 80 | $8.61 | $688.8 | 20 Mar 2026 | 20 Mar 2026 |
| Gupta AshooVP, Finance and Controller | Sale | 310 | $8.61 | $2.67K | 20 Mar 2026 | 20 Mar 2026 |
| Gupta AshooVP, Finance and Controller | Sale | 79 | $8.68 | $685.72 | 20 Dec 2025 | 23 Dec 2025 |
| Gupta AshooVP, Finance and Controller | Sale | 310 | $8.68 | $2.69K | 20 Dec 2025 | 23 Dec 2025 |
| Bizily ScottChief Legal Officer | Sale | 1,635 | $10.90 | $17.82K | 16 Dec 2025 | 19 Dec 2025 |
| Bizily ScottChief Legal Officer | Sale | 1,635 | $10.59 | $17.31K | 17 Nov 2025 | 19 Nov 2025 |
| Scott BizilyChief Legal Officer | Sale | 1,635 | $10.59 | $17.31K | 17 Nov 2025 | 19 Nov 2025 |
| Bizily ScottChief Legal Officer | Sale | 2,678 | $12.00 | $32.14K | 24 Oct 2025 | 27 Oct 2025 |
| Scott BizilyChief Legal Officer | Sale | 2,678 | $12.00 | $32.14K | 24 Oct 2025 | 27 Oct 2025 |
| Bizily ScottChief Legal Officer | Sale | 1,635 | $10.17 | $16.63K | 16 Oct 2025 | 20 Oct 2025 |
| Scott BizilyChief Legal Officer | Sale | 1,635 | $10.17 | $16.63K | 16 Oct 2025 | 20 Oct 2025 |
| Bizily ScottChief Legal Officer | Sale | 2,408 | $10.00 | $24.08K | 09 Oct 2025 | 14 Oct 2025 |
| Scott BizilyChief Legal Officer | Sale | 2,408 | $10.00 | $24.08K | 09 Oct 2025 | 14 Oct 2025 |
Frequently Asked Questions
What is FDMT stock price today?
4D MOLECULAR THERAPEUTICS IN (FDMT) is currently trading at $8.75. The stock has a 52-week range of $2.24 to $12.34 and a market capitalization of $499.93M.
Is FDMT a good stock to buy in 2026?
4D MOLECULAR THERAPEUTICS IN has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +123.1%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling FDMT stock?
There have been 13 insider transactions for FDMT in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has FDMT stock performed over the past year?
4D MOLECULAR THERAPEUTICS IN (FDMT) has returned +123.1% over the past 12 months. The stock traded between $2.24 and $12.34 during this period, and is currently at $8.75.
Which hedge funds own FDMT (4D MOLECULAR THERAPEUTICS IN)?
0 tracked hedge funds currently hold FDMT in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is FDMT's market cap and valuation?
4D MOLECULAR THERAPEUTICS IN (FDMT) has a market capitalization of $499.93M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is FDMT's revenue and profitability?
4D MOLECULAR THERAPEUTICS IN reported revenue of $120.00K with net income of N/A and a profit margin of N/A. The stock has a beta of 3.01.
What sector is FDMT in and who are its biggest institutional holders?
4D MOLECULAR THERAPEUTICS IN (FDMT) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.